Table III.

Pelvic Floor Symptoms with Anticholinergic Use

	Baseline (n=35)	Week 1 (n=35)	P Value	Week 4 (n=35)	P Value	Week 12 (n=15)	P Value
PFDI-20^c	107.1±54.6	101.0±57.1	0.37	90.5±61.1	0.007	58.5±41.6^a	<0.001
UDI-6^d	58.0±32.1	55.0±26.8	0.46	48.5±24.7	0.001	32.1±23.1^b	<0.001
PFIQ-7^e	62.2±65.5	65.0±73.0	0.62	49.8±60.0	0.37	35.0±31.3	0.02
UIQ-7^f	38.1±27.1	39.8±30.8	0.68	29.1±27.5	0.03	22.2±19.3	0.07
PISQ-12^g	28.5±5.8	29.2±8.0	0.60	30.6±7.1	0.19	29.3±6.2	0.08

Data presented as mean ± SD

All analyses performed with paired t-test, with outcomes compared to baseline.

^a.

p=0.01 when comparing Week 4 to Week 12

^b.

p=0.03 when comparing Week 4 to Week 12

^c.

PFDI-20 = Pelvic Floor Distress Inventory, short form

^d.

UDI-6 = Urinary Distress Inventory, short form

^e.

PFIQ-7 = Pelvic Floor Impact Questionnaire, short form

^f.

UIQ-7 = Urinary Impact Questionnaire, short form

^g.

PISQ-12 = Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire, short form